Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trialResearch in context

Summary: Background: Anlotinib is a new type of tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1/2/3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1–4 and c-Kit, with a broad spectrum of inhibitory effects on tumor angioge...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yan Liang, Jing Liu, Jia Ge, Qiyun Shi, Guozhi Zhang, Andi Wan, Tao Luo, Hao Tian, Linjun Fan, Shushu Wang, Li Chen, Peng Tang, Kai Zhu, Jun Jiang, Xiuwu Bian, Yi Zhang, Xiaowei Qi
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-05-01
Col·lecció:	EClinicalMedicine
Matèries:	Anlotinib Anti-tumor angiogenesis Triple-negative breast cancer Neoadjuvant chemotherapy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589537024001640
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!